Avalo Therapeutics, Inc. (AVTX)
NASDAQ:AVTX
Want to see AVTX full AI Analyst Report?
AVTX Stock Chart & Stats
$14.43
-$0.55(-7.32%)
At close: 4:00 PM EST
$14.43
-$0.55(-7.32%)
Day’s Range― - ―
52-Week Range$3.43 - $24.27
Previous CloseN/A
Volume10.82K
Average Volume (3M)2.10M
Market Cap
$859.45M
Enterprise Value$162.00M
Total Cash (Recent Filing)$81.99M
Total Debt (Recent Filing)$2.33M
Price to Earnings (P/E)―
Beta1.14
Next Earnings
Jul 30, 2026EPS Estimate
-0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.83
Shares Outstanding52,565,570
10 Day Avg. Volume1,757,420
30 Day Avg. Volume2,095,683
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)2.93
Price to Sales (P/S)4125.96
P/FCF Ratio-4.73
Enterprise Value/Market Cap0.19
Enterprise Value/Revenue2.75K
Enterprise Value/Gross Profit3.86K
Enterprise Value/Ebitda-1.79
Forecast
1Y Price Target
$47.11Price Target Upside226.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-3.54
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical ValidationA clear Phase 2 efficacy signal for abdakibart in hidradenitis suppurativa could validate the IL-1 class and boost confidence in the program if it shows meaningful drug‑placebo separation and favorable safety.
Market OpportunityHidradenitis suppurativa remains underpenetrated and recent expansion of the treated patient population by an approved therapy suggests space for a differentiated new entrant like abdakibart to capture meaningful market share.
Mechanism Of ActionSelective IL-1β targeting and higher potency of abdakibart could improve tolerability and expand the therapeutic window compared with dual-target agents, creating a biologically differentiated profile.
Bears Say
Clinical Success ThresholdsKey opinion leaders define specific clinical success thresholds in hidradenitis suppurativa, so failure to achieve a meaningful drug‑placebo separation could limit regulatory support and clinician uptake.
Competitive Commercial BenchmarkThe strong commercial performance of a leading IL-17 therapy sets a high bar, so abdakibart must demonstrate clear efficacy or a distinct dosing advantage to win prescriber adoption and market share.
Trial Variability And Placebo RiskA prior related trial experienced an unusually high placebo response, highlighting the risk that variable placebo noise could obscure true drug effects and lead to negative trial outcomes.
Avalo Therapeutics News
AVTX FAQ
What was Avalo Therapeutics, Inc.’s price range in the past 12 months?
Avalo Therapeutics, Inc. lowest stock price was $3.43 and its highest was $24.27 in the past 12 months.
What is Avalo Therapeutics, Inc.’s market cap?
Avalo Therapeutics, Inc.’s market cap is $859.45M.
When is Avalo Therapeutics, Inc.’s upcoming earnings report date?
Avalo Therapeutics, Inc.’s upcoming earnings report date is Jul 30, 2026 which is in 64 days.
How were Avalo Therapeutics, Inc.’s earnings last quarter?
Avalo Therapeutics, Inc. released its earnings results on May 13, 2026. The company reported -$0.98 earnings per share for the quarter, beating the consensus estimate of -$1.025 by $0.045.
Is Avalo Therapeutics, Inc. overvalued?
According to Wall Street analysts Avalo Therapeutics, Inc.’s price is currently Undervalued.
Does Avalo Therapeutics, Inc. pay dividends?
Avalo Therapeutics, Inc. does not currently pay dividends.
What is Avalo Therapeutics, Inc.’s EPS estimate?
Avalo Therapeutics, Inc.’s EPS estimate is -0.62.
How many shares outstanding does Avalo Therapeutics, Inc. have?
Avalo Therapeutics, Inc. has 52,565,570 shares outstanding.
What happened to Avalo Therapeutics, Inc.’s price movement after its last earnings report?
Avalo Therapeutics, Inc. reported an EPS of -$0.98 in its last earnings report, beating expectations of -$1.025. Following the earnings report the stock price went down -0.451%.
Which hedge fund is a major shareholder of Avalo Therapeutics, Inc.?
Currently, no hedge funds are holding shares in AVTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Avalo Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$47.11 (226.48% Upside)
$47.11 (226.48% Upside)
Blogger Sentiment
Bullish
AVTX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 894.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $411.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 14.5%
Last 30 Days ▲ 14.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
327.20%
12-Months-Change
Fundamentals
Return on Equity
-97.55%
Trailing 12-Months
Asset Growth
-27.89%
Trailing 12-Months
Company Description
Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease, including adult-onset still's disease and systemic juvenile idiopathic arthritis. Its products for rare genetic diseases in Phase III clinical trials include AVTX-801, a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, a L-fucose substrate replacement therapy for the treatment of LADII, also known as SLC35C1-CDG. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
AVTX Stock 12 Month Forecast
Average Price Target
$47.11
▲(226.48% Upside)
Technical Analysis
Corbus Pharmaceuticals
―
Forte Biosciences
―
Milestone Pharmaceuticals
―
Elicio Therapeutics
―
Fractyl Health, Inc.
―
Ownership Overview
0.71% Insiders
2.26% Mutual Funds
40.95% Other Institutional Investors
54.40% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---